Management of Atrial Fibrillation
completed: May 1999 Investigators Robert L. McNamara, MD, MHS
Marlene R. Miller, MD
Jodi B. Segal, MD, MPH
Steven N. Goodman, MD, PhD
Nina L. Kim, MA
Karen A. Robinson, MSc
Neil R. Powe, MD, MPH, MBA
Eric B. Bass, MD, MPH
Questions
Key, supplementary and secondary questions were identified. The following key questions were addressed: Which patients with new onset atrial fibrillation should receive attempts at cardioversion and which should only receive conservative treatment with rate control and thromboembolism prophylaxis? What is the efficacy of electrical cardioversion alone compared with antiarrhythmic therapy alone compared with both together for patients with new onset atrial fibrillation? What are the risks and benefits of each of the antiarrhythmic agents used in the management of atrial fibrillation? What types of therapy for atrial fibrillation can safely be performed as an outpatient rather than as an inpatient? What is the diagnostic value of tests, such as transesophageal echocardiography and transthoracic echocardiography, that cane be used in the evaluation of patients with new onset atrial fibrillation?
link to summary of report on AHRQ site link to evidence report on AHRQ site
|
